Among many tested against melanoma, these include the use of IFNAR1 (Interferon Alpha And Beta Receptor Subunit 1) to augment the combination of inflammatory adjuvants [33], and H9T, an engineered IL-2 partial agonist that promotes the expression of T-cell transcription factor 1 and CAR-modified CD8+T cells, yielding greater tumor infiltration and survival [34]. Here, IL2 is linked to melanoma.